NCT03028974View on ClinicalTrials.gov

Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)

PHASE4CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

September 17, 2014

Primary Completion Date

November 20, 2017

Study Completion Date

November 20, 2017

Conditions
Influenza
Interventions
BIOLOGICAL

Fluzone®

Fluzone® Quadrivalent: Quadrivalent influenza virus vaccine

BIOLOGICAL

FluMist®

FluMist® Quadrivalent: Quadrivalent influenza virus vaccine live, intranasal spray

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Stanford University

OTHER

NCT03028974 - Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029) | Biotech Hunter | Biotech Hunter